Biomarkers of Aggressiveness in Prostate Cancer

Olivier, Cuvillier; Malavaud, Bernard

doi:10.5772/25310

Cited by 3 publications

(6 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The usage of biomarkers for PCa screening, detection, and prognosis have transformed the diagnosis and management of the disease. Introduction of prostate-specific antigen (PSA) test in clinical practice has ensured early identification and decreased mortality from PCa (2). In spite of its ample value for PCa detection, PSA as a solitary test has some restrictions.…”

Section: Introductionmentioning

confidence: 99%

A New Era of Prostate Cancer Precision Medicine

2019

View full text Add to dashboard Cite

Prostate cancer is the second most common male cancer affecting Western society. Despite substantial advances in the exploration of prostate cancer biomarkers and treatment strategies, men are over diagnosed with inert prostate cancer, while there is also a substantial mortality from the invasive disease. Precision medicine is the management of treatment profiles across different cancers predicting therapies for individual cancer patients. With strategies including individual genomic profiling and targeting specific cancer pathways, precision medicine for prostate cancer has the potential to impose changes in clinical practices. Some of the recent advances in prostate cancer precision medicine comprise targeting gene fusions, genome editing tools, non-coding RNA biomarkers, and the promise of liquid tumor profiling. In this review, we will discuss these recent scientific advances to scale up these approaches and endeavors to overcome clinical barriers for prostate cancer precision medicine.

show abstract

Section: Introductionmentioning

confidence: 99%

A New Era of Prostate Cancer Precision Medicine

2019

View full text Add to dashboard Cite

show abstract

“…A common urine-based biomarker is PCA3 (formerly DD3), a prostate specific non-coding RNA [29,30,32,36]. The reported studies [20,21,25,28,[37][38][39] showed an AUC ranging from 0.64-0.74 for PCA3.…”

Section: A In-vitro Prostate Cancer Diagnostic Technologiesmentioning

confidence: 99%

“…Additionally, these tests require a physical sample, wether it be blood or urine [29]. This is also true for needle biopsies, which are highly invasive and can cause physical harm to patients (e.g., bleeding).…”

Section: A In-vitro Prostate Cancer Diagnostic Technologiesmentioning

confidence: 99%

“…In addition, α-methylacyl-CoA racemase (AMACR) is yet another researched biomarker [30]. It can be used in a blood-based, a urine-based, or a tissue-based (after biopsy) test for diagnosing prostate cancer [29]. AMACR is an enzyme utilized in the synthesis and the oxidative metabolism of branched fatty acids [30].…”

Section: A In-vitro Prostate Cancer Diagnostic Technologiesmentioning

confidence: 99%

“…Other blood-based biomarkers have been researched for diagnosing prostate cancer, such as the early prostate cancer antigen (EPCA) [29,30]. EPCA is a nuclear matrix protein that showed a promising results for diagnosing prostate cancer [31,32].…”

Section: A In-vitro Prostate Cancer Diagnostic Technologiesmentioning

confidence: 99%

See 2 more Smart Citations

A novel NMF-based DWI CAD framework for prostate cancer.

McClure¹

View full text Add to dashboard Cite

Insights for public education provided by French media on ideas about prostate cancer – A media analysis study

Zanchetta¹,

Cognet²,

Lam-Kin-Teng³

et al. 2018

Health Promot Perspect

View full text Add to dashboard Cite

Background: This study explored the French media’s presentation of ideas and medical information about prostate cancer (PC) that may influence men’s understanding, attitudes and behavior. Methods: A qualitative media content analysis centered on PC information delivered by French professional media. The selected data were produced in the aftermath of the High Health Authority's decision in 2008 not to recommend systematic screening by prostate specific antigen(PSA) for men over 50. Source was the Media Archives of the French National Library. Content was analyzed from 15 television programs, 14 radio programs, and 55 articles from 35 popular French newspapers (online and printed, weekly and monthly) and 20 magazines. Audio content was narrated into textual form and submitted to manual coding along with the print content.Results: Television and radio content focused on the nature of PC, screening and treatment,and conveyed a gender-centric position linked to male sexuality and virility. Newspapers and magazines targeted the testing controversy, the lack of consensus among professionals, and scientific advances in screening and treatment.Conclusion: Media participation in the European testing debate is valuable for allowing patients to hear all opinions on PC risk factors. Debate on testing policy contributes to confusion and uncertainty regarding appropriate action.

show abstract

Biomarkers of Aggressiveness in Prostate Cancer

Cited by 3 publications

References 94 publications

A New Era of Prostate Cancer Precision Medicine

A New Era of Prostate Cancer Precision Medicine

A novel NMF-based DWI CAD framework for prostate cancer.

Insights for public education provided by French media on ideas about prostate cancer – A media analysis study

Contact Info

Product

Resources

About